Tecentriq Hybreza (Atezolizumab and Hyaluronidase-Tqjs) for Lung Cancer

Overview
Tecentriq Hybreza, a combination of atezolizumab and hyaluronidase, is approved by the U.S. Food and Drug Administration (FDA) for treating various forms of lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). For NSCLC, it is used as an adjuvant therapy (additional treatment after the main treatment) following surgery and chemotherapy in adults with stage 2 to 3A NSCLC, provided their tumors express PD-L1 (a protein that helps cancer cells evade the immune system). It is also used as a first-line treatment in adults with metastatic (advanced) NSCLC whose tumors express high levels of PD-L1 and do not have certain genetic mutations (EGFR or ALK). Tecentriq Hybreza may be used in combination with other drugs like bevacizumab, paclitaxel, and carboplatin. In individuals with SCLC, Tecentriq Hybreza is used with chemotherapy for the first-line treatment of extensive-stage disease. Tecentriq Hybreza is also known by its drug name, atezolizumab and hyaluronidase-tqjs.

Tecentriq Hybreza is classified as an immunotherapy. It works by blocking the PD-L1 protein, which allows the immune system to better detect and attack cancer cells. Hyaluronidase helps the atezolizumab to be absorbed more effectively when given subcutaneously (under the skin).

How do I take it?
Prescribing information states that Tecentriq Hybreza is administered as a subcutaneous injection in the thigh. For lung cancer, it is given every three weeks. When used as an adjuvant therapy for NSCLC, it is typically given following surgery and chemotherapy for up to one year. For metastatic NSCLC or SCLC, Tecentriq Hybreza may be used alone or in combination with chemotherapy and other agents. The injection is administered by a health care provider, and it must be taken exactly as prescribed.

Side effects
Common side effects of Tecentriq Hybreza include fatigue, musculoskeletal pain, cough, shortness of breath, and loss of appetite.

Rare but serious side effects may include immune-mediated adverse reactions affecting organs and tissues, such as pneumonitis (lung inflammation), colitis (inflammation of the colon), hepatitis (liver inflammation), endocrinopathies (hormonal disorders), and nephritis (kidney inflammation). Fatal and other serious complications may also occur in individuals who receive hematopoietic stem cell transplantation before or after being treated with a PD-1/PD-L1 blocking antibody.  

For more information about this treatment, visit:

Tecentriq Hybrezatm (Atezolizumab and Hyaluronidase-Tqjs) Injection, for Subcutaneous Use — U.S. Food & Drug Administration

Tecentriq Hybreza — Drugs.com